JAC Advance Access published online on June 17, 2004
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkh258
© 2004 by The British Society for Antimicrobial Chemotherapy
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 The Triangle Research and Development Center, Kfar-Qaraa, Israel
* To whom correspondence should be addressed. E-mail: erubins{at}yahoo.com.
Objective: Long-term therapy for anthrax might induce antimicrobial resistance in Bacillus anthracis. The aim of the present study was to investigate the potential of 18 different antibiotics to select resistant isolates of B. anthracis, (ST-1 and Sterne strains). Methods: Resistant isolates were selected by serial passages on brain heart infusion agar containing increasing concentrations of antibiotics (from the MIC upwards). Results: The MICs of ciprofloxacin, ofloxacin and levofloxacin increased from 0.125-0.25 to 8 mg/L, that of moxifloxacin increased from 0.03-0.06 to 8 mg/L, in both strains, and the MIC of garenoxacin increased from 0.015 to 0.5 mg/L for the ST-1 strain and from 0.03 to 8 mg/L for the Sterne strain. The MICs of tetracycline and minocycline increased from 0.125 to 2-8 mg/L and 0.06 to 1 mg/L, respectively. The MIC of vancomycin increased from 2.5 to 20 mg/L for the ST-1 strain and from 5 to 20 mg/L for the Sterne strain. Linezolid exhibited an MIC increase from 2 to 4 mg/L for both strains. The MIC of quinupristin/dalfopristin increased from 0.125 to 64-128 mg/L. Erythromycin demonstrated an MIC increase from 1 to 128 mg/L, that of clarithromycin increased from 0.125 to 8-64 mg/L and that of telithromycin increased from 0.06-0.125 to 1-4 mg/L. The clindamycin MIC increased from 0.125-0.25 to 8 mg/L. Penicillin G and amoxicillin MICs increased from <1 mg/L to 128-512 mg/L. Isolates made resistant to one fluoroquinolone exhibited cross-resistance to the other quinolones except the ST-1 mutant strain which remained susceptible to garenoxacin. Cross-resistance to fluoroquinolones did not correlate with resistance to other antibiotics. Conclusion: The ease with which B. anthracis can be made resistant in vitro suggests that close monitoring of patients treated for anthrax is mandatory.
Revised March 22, 2004
Accepted March 30, 2004
Original article
Selection of Bacillus anthracis isolates resistant to antibiotics
2 The Triangle Research and Development Center, Kfar-Qaraa, Israel; Department of Human Microbiology, Tel-Aviv University School of Medicine, Tel-Aviv, Israel
3 Toronto Centre for Antimicrobial Research & Evaluation (ToCARE), Department of Microbiology, Mount Sinai Hospital Toronto, Ontario, Canada
4 Department of Human Microbiology, Tel-Aviv University School of Medicine, Tel-Aviv, Israel; Infectious Diseases Unit, Sheba Medical Center, Tel-Aviv University School of Medicine, Tel Hashomer, Israel
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  V. A. Luna, D. S. King, J. Gulledge, A. C. Cannons, P. T. Amuso, and J. Cattani Susceptibility of Bacillus anthracis, Bacillus cereus, Bacillus mycoides, Bacillus pseudomycoides and Bacillus thuringiensis to 24 antimicrobials using Sensititre(R) automated microbroth dilution and Etest(R) agar gradient diffusion methods J. Antimicrob. Chemother., September 1, 2007; 60(3): 555 - 567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Pelat, M. Hust, E. Laffly, F. Condemine, C. Bottex, D. Vidal, M.-P. Lefranc, S. Dubel, and P. Thullier High-Affinity, Human Antibody-Like Antibody Fragment (Single-Chain Variable Fragment) Neutralizing the Lethal Factor (LF) of Bacillus anthracis by Inhibiting Protective Antigen-LF Complex Formation Antimicrob. Agents Chemother., August 1, 2007; 51(8): 2758 - 2764. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Dodd, J. G. Reese, C. R. Louer, J. D. Ballard, M. A. Spies, and S. R. Blanke Functional Comparison of the Two Bacillus anthracis Glutamate Racemases J. Bacteriol., July 15, 2007; 189(14): 5265 - 5275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. C. Kedar, V. Brown-Driver, D. R. Reyes, M. T. Hilgers, M. A. Stidham, K. J. Shaw, J. Finn, and R. J. Haselbeck Evaluation of the metS and murB Loci for Antibiotic Discovery Using Targeted Antisense RNA Expression Analysis in Bacillus anthracis Antimicrob. Agents Chemother., May 1, 2007; 51(5): 1708 - 1718. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Yoong, R. Schuch, D. Nelson, and V. A. Fischetti PlyPH, a Bacteriolytic Enzyme with a Broad pH Range of Activity and Lytic Action against Bacillus anthracis. J. Bacteriol., April 1, 2006; 188(7): 2711 - 2714. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Mabry, M. Rani, R. Geiger, G. B. Hubbard, R. Carrion Jr, K. Brasky, J. L. Patterson, G. Georgiou, and B. L. Iverson Passive Protection against Anthrax by Using a High-Affinity Antitoxin Antibody Fragment Lacking an Fc Region Infect. Immun., December 1, 2005; 73(12): 8362 - 8368. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Athamna, M. Athamna, A. Nura, E. Shlyakov, D. J. Bast, D. Farrell, and E. Rubinstein Is In Vitro Antibiotic Combination More Effective than Single-Drug Therapy against Anthrax? Antimicrob. Agents Chemother., April 1, 2005; 49(4): 1323 - 1325. [Abstract] [Full Text] [PDF]
|
|